Compared to other malignancies, the mutational landscape of MPN shows high homogeneity, as 98% of patients with PV and 50–60% of patients with PMF and ET harbor the Janus kinase 2 (JAK2) V617F mutation [11]. This evidence concerns the gene JAK2 and essential thrombocythemia.